Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay
Acquired resistance to oncogene-targeted therapies is the major driver of mortality for patients with cancer. Here, we present a 6-to-16-week assay to model the development of acquired resistance in adherent and suspension cancer cell lines. We describe steps for determining therapeutic dose, assaying acquired resistance, and testing combination therapies. This protocol is a high-throughput, cost-effective, and scalable method to model acquired drug resistance to established and newly developed therapies. For complete details on the use and execution of this protocol, please refer to Sealover et al.<sup>1</sup> and Theard et al.<sup>2</sup>.
Authors
- Amanda J. Linke (ORCID: https://orcid.org/0000-0001-5719-9696)
- Brianna R. Daley (ORCID: https://orcid.org/0009-0008-3018-9963)
- Robert L. Kortum (ORCID: https://orcid.org/0000-0002-1634-4882)
- Nancy E. Sealover (ORCID: https://orcid.org/0000-0002-6463-5836)
- Deepan Chatterjee (ORCID: https://orcid.org/0000-0001-7997-7014)
- Bridget A. Finniff (ORCID: https://orcid.org/0009-0004-9331-9535)
- Robert E. Lewis (ORCID: https://orcid.org/0000-0002-3616-2971)
- Jacob M. Hughes (ORCID: https://orcid.org/0009-0007-6686-5014)
- Patricia L. Theard (ORCID: https://orcid.org/0000-0001-9761-7645)
Institutions
- Uniformed Services University of the Health Sciences (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- STAR Protocols
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1016/j.xpro.2024.103361
- Citations
- 6
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.43
Funders
- U.S. Department of Defense
- Foundation for the National Institutes of Health
- National Institutes of Health
- Uniformed Services University of the Health Sciences
- Congressionally Directed Medical Research Programs